Humana Inc. Q3 FY2025 earnings call

• Solid third quarter performance in line with expectations. • Medical cost trends in line with expectations. • Full year 2025 EPS outlook remains approximately $17. • Focus on product and experience to drive customer retention and growth. • Clinical excellence to deliver clinical outcomes and medical margin. • Highly efficient operations with initiatives like partnering with Genpact and agentic AI platform. • Capital allocation including selling non-core assets and deploying capital to Villages Health. • Balance sheet efficiency efforts with days in claims payable metric and ongoing asset sales.

No detailed breakdown of product segment financial performance and revenue contribution % provided in the transcript.

• Reaffirmed full year adjusted EPS outlook of approximately $17. • '25 outlook includes Doc Fix; if not implemented, savings may be invested in long-term success. • Prudent near-term capital deployment approach, no additional share repurchase activity planned beyond second quarter buybacks. • See opportunities in M&A to acquire small to midsized provider businesses while managing debt-to-cap ratio.

• Certain matters discussed are forward-looking and involve risks and uncertainties. Actual results could differ materially. Risks detailed in latest Form 10-K and other SEC filings.

Q: Andrew Mok asked about framework for new growth and if levers are being pulled.

A: David Dintenfass discussed focus on lifetime value and NPV, balancing pricing, product, and customer focus, working dynamically on operations.

Q: Ann Hynes asked about diversification strategy, shifting members out of H5216.

A: James Rechtin said goal is to deconsolidate H5216, made progress, will share more in January.

Q: Justin Lake asked about new membership expectation range and MA individual membership in fully capitated agreements.

A: James Rechtin said no specific number, George Renaudin talked about taking Part D risk back and Stars mitigation programs.

Q: Stephen Baxter asked about margin for new to Humana sales.

A: Celeste Mellet said margin depends on contracts, happy with seen margin, expect relatively consistent.

Q: Benjamin Hendrix asked about Stars recovery efforts.

A: James Rechtin and George Renaudin talked about broad improved performance in metrics and stability contributing to CAHPS.

Q: Kevin Fischbeck asked about MLR and disenrollment.

A: James Rechtin talked about channel dynamics, NPV, cost of acquisition, and engagement rates.

Q: Joshua Raskin asked about LTV and NPV strategic shift.

A: David Dintenfass and Celeste Mellet discussed evolution towards integrated health and balancing long-term and short-term.

Q: A.J. Rice asked about MA market and mitigation efforts.

A: James Rechtin said market growth expected mid-single digits, David Dintenfass talked about decommissioning plans as a lever.

Q: Elizabeth Anderson asked about MA membership impact and 2026 margin.

A: Celeste Mellet said better retention and sales drove membership, no impact to MLR expectations.

Q: Scott Fidel asked about product mix and LIS PDP growth.

A: David Dintenfass said early, even growth; George Renaudin talked about PDP growth from basic and value plans.

Q: Ryan Langston asked about not crosswalking group MA members from H5216.

A: James Rechtin said balanced portfolio, stability, and Stars outlook led to decision.

Q: Jason Cassorla asked about medical and pharmacy trends and clinical excellence.

A: Celeste Mellet said trends expected to continue, early to quantify clinical excellence opportunity.

Q: Lance Wilkes asked about margin characteristics and direct-to-employer.

A: George Renaudin talked about Medicaid dual margins and James Rechtin mentioned direct-to-employer opportunities in pharmacy.

Q: Michael Ha asked about '27 advanced rate notice.

A: Celeste Mellet said not commenting on rate notice specifics.

Q: Benjamin Mayo asked about social risk factors and duals mix.

A: George Renaudin talked about progress in social risk factors and good mix of membership